Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms

Obstetrics and Gynecology

Volumn 102, Issue 4, 2003, Pages 823-834

  Speroff, Leon ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL;

ADULT; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; GOOD GENERAL CONDITION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MENOPAUSAL SYNDROME; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCALE UP; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UROGENITAL SYSTEM; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA RING; VASOMOTOR DISORDER;

EID: 0141459442     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(03)00764-6     Document Type: Article

References (21)

1. Willhite L.A., O'Connell M.B. Urogenital atrophy Prevention and treatment . Pharmacotherapy. 21:2001;464-480.
2. Kaufman J.M. Pharmacokinetics of oestrogens and hormone replacement therapy. Eur Menopause J. 4:1997;14-22.
3. Ettinger B., Pressman A. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization Transdermal matrix patch versus oral estrogen therapy . Am J Managed Care. 5:1999;779-785.
4. Ayton R.A., Darling G.M., Murkies A.L., Farrel E.A., Weisberg E., Selinus I., et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with a conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol. 103:1996;351-358.
5. McKinney K.A., Thompson W. A practical guide to prescribing hormone replacement therapy. Drugs. 56:1998;49-57.
6. Barentsen R., van de Weijer P.H.M., Schram J.H.N. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol. 71:1997;73-80.
7. Henriksson L., Stjernquist M., Boquist L., Cedergran I., Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 174:1996;85-92.
8. Estring estradiol vaginal ring. 2001;Pharmacia & Upjohn, Kalamazoo, Michigan. [package insert].
9. Passmore C., Knox N., McNamee B., deVries T. Serum oestradiol concentrations following single-dose administration of oestradiol acetate intravaginal rings (IVRs) delivering 50, 75, and 100 μg/day oestradiol in healthy postmenopausal women. J Br Menopause Soc. 7:(Suppl S3):2001;30.
10. Bachmann G. The estradiol vaginal ring A study of existing clinical data . Maturitas. 22:(Suppl):1995;S21-28.
11. Notelovitz M. Urogenital atrophy and low-dose vaginal estrogen therapy. [editorial] Menopause. 7:2000;140-142.
12. Hammond D.O. Cytological assessment of climacteric patients. Clin Obstet Gynaecol. 4:1977;49-70.
13. Hustin J., van den Eynde J.P. Cytologic evaluation of the effect of various estrogens given in postmenopause. Acta Cytol. 21:1977;225-228.
14. Greene J.G. Constructing a standard climacteric scale. Maturitas. 29:1998;25-31.
15. Keppel G., Zedeck S. Data analysis for research designs: Analysis of variance and multiple regression/correlation approaches. 1989;W. H. Freeman and Company, New York.
16. Climara estradiol transdermal system. 2001;Berlex Laboratories, Wayne, New Jersey. [package insert].
17. Vivelle-Dot estradiol transdermal system. 2002;Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. [package insert].
18. Casper F., Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring A comparative and a placebo-controlled multicenter study . Int Urogynecol J. 10:1999;171-176.
19. Al-Azzawi F, Buckler H. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for vasomotor menopausal symptoms. Climacteric. 2003;6:118-27.
20. Buckler H., Perry W. The effect on climacteric symptoms of oestrogen replacement therapy with an oestradiol acetate intravaginal ring in postmenopausal women. J Br Menopause Soc. 7:(Suppl S3):2001;23-24.
21. Bachmann G.A. The clinical platform for the 17β-estradiol vaginal releasing ring. Am J Obstet Gynecol. 178:1998;S257-260.